Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camrelizumab, Apatinib, and Tegio in Refractory Advanced Gastric Cancer
NCT04345783Phase 2Unknown
- Sponsor
- Beijing Friendship Hospital
- Start
- Jan 2018
- Primary completion
- Dec 2021
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of camrelizumab in gastric cancer (GC), gastroesophageal junction adenocarcinoma, sponsored by Beijing Friendship Hospital. Status: unknown.
02
Drugs
camrelizumab
03
Conditions
gastric cancer (GC)gastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT04345783.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04345783.